Biorbyt
![]() |
||
Products for advancing your discoveries From antibodies to proteins, biochemicals to ELISA kits, Biorbyt's high quality research products are available for you to enable world class research and contribution to a deeper understanding of life sciences.
A comprehensive catalog of life science research products covering the areas of Neuroscience, Signal transduction, Cell Biology, Cancer Metabolism, Cardiovascular and others
Product range :
Choose from over 100,000 primary antibodies and over 2,000 secondary antibodies. Monoclonals and polyclonals tested in a number of applications - WB, ELISA, IHC, FACS and many more.
Choose from over 7,000 proteins and over 400 active proteins. All of our proteins have been validated for use in ELISAs, WB and IHC-P
We have over 10,000 biochemicals for use in your research.
We have over 2,000 ELISA kits covering many research areas . Each kit comes with a fully detailed protocol and examples of expected results.
Website : https://www.biorbyt.com/
|
![Obeticholic Acid](https://www.clinisciences.com/de/upload/bandeau3-9pw8hz2z-7wuq4zmd-b664f4-w4k4gg.png)
Obeticholic Acid
Obeticholic acid (OCA) is a synthetic derivative of the endogenous primary bile acid, chenodeoxycholic acid, and is primarily used to treat liver and bile duct pathologies. It has been approved by the FDA for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA. OCA has also been studied for its potential use in treating non-alcoholic steatohepatitis (NASH).
The mechanism of action of OCA involves reducing hepatic exposure to bile acids, which limits the progression of cholangitic processes such as PBC and primary sclerosing cholangitis (PSC). OCA is a first-in-class agonist that selectively binds to the farnesoid X receptor (FXR). This leads to direct and indirect suppression of bile acid production in the liver and increased bile flow, resulting in reduced exposure of the liver to toxic levels of bile acids. This reduced exposure should clinically translate into decreased parenchymal liver injury caused by bile acids, leading to improved biochemical enzyme profiles and decreased disease progression of PBC.
Ergebnis Ihrer Suche : 29 Produkt(e) gefunden
Grenzen Sie Ihre Suche ein :
- Biochemicals